Is ORXOF or QYLD a better dividend investment in 2026?

ORXOF currently yields 87.48% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: ORXOF offers higher current income.

What is the dividend yield difference between ORXOF and QYLD?

ORXOF has a forward dividend yield of 87.48% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 75.56 percentage points.

Home › Compare › ORXOF vs QYLD

ORXOF vs QYLD: Dividend Comparison 2026

ORXOF yields 87.48% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ORXOF wins by $2.28M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ORXOF

● Live price

87.48%

Share price

$2.29

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2.30M

Annual income

$708,964.09

Full ORXOF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — ORXOF vs QYLD

📍 ORXOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ORXOF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ORXOF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ORXOF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORXOF

Annual income on $10K today (after 15% tax)

$7,435.92/yr

After 10yr DRIP, annual income (after tax)

$602,619.48/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, ORXOF beats the other by $597,809.06/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORXOF + QYLD for your $10,000?

ORXOF: 50%QYLD: 50%

100% QYLD50/50100% ORXOF

Portfolio after 10yr

$1.16M

Annual income

$357,311.71/yr

Blended yield

30.69%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORXOF buys

QYLD buys

No recent congressional trades found for ORXOF or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricORXOFQYLD

Forward yield	87.48% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$2.30M	$25.4K ✓
Annual income after 10y	$708,964.09 ✓	$5,659.31
Total dividends collected	$2.02M	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: ORXOF vs QYLD ($10,000, DRIP)

Year	ORXOF Portfolio	ORXOF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$19,448	$8,748.14	$10,352	$1,192.36	+$9.1K → ORXOF
2	$36,710	$15,900.47	$10,830	$1,347.57	+$25.9K → ORXOF
3	$67,330	$28,049.97	$11,460	$1,539.07	+$55.9K → ORXOF
4	$120,123	$48,080.71	$12,275	$1,777.84	+$107.8K → ORXOF
5	$208,701	$80,169.36	$13,323	$2,078.95	+$195.4K → ORXOF
6	$353,484	$130,173.43	$14,667	$2,463.34	+$338.8K → ORXOF
7	$584,283	$206,054.85	$16,396	$2,960.57	+$567.9K → ORXOF
8	$943,494	$318,311.52	$18,631	$3,612.97	+$924.9K → ORXOF
9	$1,489,918	$480,379.75	$21,548	$4,482.15	+$1.47M → ORXOF
10	$2,303,177	$708,964.09	$25,398	$5,659.31	+$2.28M → ORXOF

ORXOF vs QYLD: Complete Analysis 2026

ORXOF — Stock

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Full ORXOF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this ORXOF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORXOF vs SCHD ORXOF vs JEPI ORXOF vs O ORXOF vs KO ORXOF vs MAIN ORXOF vs XYLD ORXOF vs JEPQ ORXOF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.